Washington D.C., USA, 22-27 July 2012www.aids2012.org An advocacy tool: Untangling the Web of Antiretroviral Price Reductions Arax Bozadjian HIV Focused.

Slides:

Advertisements

Similar presentations

1 Introduction to the medicine prices and availability survey and training workshop Presentation template for adaptation and use in medicine prices and.

Advertisements

Price Reporting Mechanism (PRM): Lessons learnt and how to use the evidence from the PRM Technical Briefing Seminar for Consultants on Procurement and.

Differential pricing and access to medicines: issues and options Andrew Creese Essential Drugs and Medicines Policy Health Technology and Pharmaceuticals.

Inter-American Development Bank Procurement of Goods, Works and Consulting Services in projects financed by IDB Washington, DC – February 2004.

Inter-American Development Bank Procurement of Goods, Works and Consulting Services in projects financed by IDB Washington, DC – July 2004.

The Medicines Patent Pool advancing innovation, expanding access, promoting public health Charles Clift Chair, Medicines Patent Pool

XIX International AIDS Conference July 2012 Washington DC, USA The Brazilian experience: the campaign for access to lopinavir/ritonavir and efavirenz compulsory.

Role of Pharmacoeconomics in a Developing country context Gavin Steel for Anban Pillay Cluster Manager: Health Economics National Department of Health.

Transposition of Consumer Rights ERGEG Monitoring Report Christina Veigl-Guthann, ERGEG Task Force Chair.

Washington D.C., USA, July 2012www.aids2012.org Economic Evaluation of the National Program to Prevent Mother-to-Child Transmission of HIV in Ghana.

Unveiling the WTO August 30 Decision: The Canadian Experience Rachel Kiddell-Monroe President, Universities Allied for Essential Medicines; Former Coordinator.

Canada’s Paragraph 6 Legislation: What next? Rachel Kiddell-Monroe Coordinator for Access to Essential Medicines Campaign, MSF Canada.

1 Medicine prices and availability, evidence for policy Technical Briefing Seminar, November 3 rd 2010 Alexandra Cameron, Department of Essential Medicines.

“Using Competition Law to Promote Access to Health Technologies” Access to Innovation: Making Generic Versions of Newer ARVs Affordable 24 July 2014 Melbourne,

Health Professional Students AIDS Advocacy Network Treat the People: Access to Essential AIDS Medications A Primer for Health Professional Students.

International Experience in Pharmaceutical Services for Promoting Access to Medicines: Canada, Cuba, England, Mexico International Seminar on the Challenges.

Index 2008Index 2010 # Companies Originators 1820 # Companies Generic Manufacturers 2 Same Index, adjusted weights 7 Separate Index, adjus weights / KPIs.

Can we create a global trade framework for health care R&D that puts patients first? James Love Consumer Project on Technology Washington, DC Presented.

Access to HIV/AIDS, Tuberculosis and Malaria Medicines. WHO/UNICEF Technical Briefing Seminar on Essential Medicines Policies. Geneva, 18 – 22 September.

Application of an International Reference Price List to National Medicines Procurement Tenders Bada Pharasi, Gavin Steel, Jean-Pierre Sallet, SPS, Management.

Affordability of HIV/AIDS treatment in developing countries: modeling ARV drug price determinants for a better understanding of the market functioning.

Access to Innovation: Making Generic Versions of Newer Antiretrovirals Affordable Focusing on middle income countries Leena Menghaney, MSF Access Camapign.

Pricing and Reimbursement Policies 1. Pricing Policies Patented Medicines Maximum retail prices capped by Ministry of Economy (mainly for private sector)

Assessing the impact of TRIPS-plus provisions on Public Healh: Lessons from Latin America David Vivas Eugui WTO Public Forum CSEND Roundtable.

The UNITAID-funded MSF diagnostics project: Plans to incorporate the new WHO recommendations and how best practices will be shared with, and disseminated.

A very short introduction to patents & access to medicines.

The Role of TNCs and AIDS drugs – “Lives before profits”? L.O.s 1.To define the terms: TNC, Generic, “Big Pharma”, ARVs, HAART, Tiered Pricing. 2.To describe.

Antiretrovirals Pricing: The Past, The Present, The Future Janice Lee.

New Treatment Opportunity: Valganciclovir

Washington D.C., USA, July 2012www.aids2012.org Intellectual Property-related challenges: A Latin America Perspective GraciaVioleta Ross

UNITAID The HIV/AIDS Medicines Patent Pool Initiative October 2010.

Lucia Green-Weiskel Innovation Center for Energy and Transportation (iCET) Panel on Reporting and Public Disclosure Washington DC, March 22, 2010 Carbon.

Marketing for Prevention: “Getting the Message” Presented by Camille L. Lashlee, M.A. Prevention Services Manager.

UK Policy considerations on increasing access to medicines for the poor in developing countries. DEPARTMENT FOR INTERNATIONAL DEVELOPMENT.

The competition between innovative and generic pharmaceutical companies intensified in the last decades. The models created by innovative pharmaceutical.

Drug Prices in Canada and the US: More Than Meets the Eye? National Academy of Social Insurance Annual Conference Wayne Critchley Executive Director, PMPRB.

Summary: Biological Therapeutics for Rare Plasma Protein Disorders Workshop July 21, 2005 Mark Weinstein, Ph.D. Office of Blood Research and Review CBER,

RHSC Meeting Kampala, May 2010 Quality for Medicines The Global Fund approach Sophie Logez Manager, QA and Data Quality Pharmaceutical Management.

Washington D.C., USA, July 2012www.aids2012.org Why do we need patent landscapes and what tools can be made available? Presenting the UNDP Patent.

Medicine Prices, Availability, Affordability and Price Components in Kazakhstan, Kyrgystan, Tajikistan & Uzbekistan Margaret Ewen Health Action International.

Paula Munderi Department of Essential Drugs and Medicines Policy World Health Organization Access to essential medicines for HIV/AIDS - update on WHO activities.

UNCTAD/CD-TFT 1 Exclusive Rights and Public Access – Flexibilities in International Agreements and Development Objectives The Public Health Example 21.

IDENTIFYING COMPETITIVE ADVANTAGES Three common tools used in industry to analyze and develop competitive advantages include: – Porter’s Five Forces Model.

Washington D.C., USA, July 2012www.aids2012.org Methodology to Determine the Patent Status of Key ARVs and Other Essential Medicines: A Strategy.

1 Determining Value for Innovation and Setting Prices Richard Laing EDM/PAR WHO.

Lessons learned from the Global Fund’s Price and Quality Reporting (PQR) database T Patrick Aylward, Sophie Logez, Thuy Huong Ha, Monika Zweygarth, Carmen.

PATENT POOL & its CONCERNS PATENT POOL & its CONCERNS Manmohan A Amonkar 20 July 2010.

Medicines and the Poor: What Role for Competition Law & Policy? Mariana Tavares de Araujo Competition Department, Head SDE, Ministry of Justice, Brazil.

Zokufa HZ, Pillay T Pharmaceutical Policy and Planning National Department of Health- South Africa.

Ellen ‘t Hoen Médecins sans Frontières

Washington D.C., USA, July 2012www.aids2012.org Patent Oppositions in Argentina International AIDS Conference July 2012 M. Lorena Di Giano.

Washington D.C., USA, July 2012www.aids2012.org Bottlenecks analysis – a critical step to evidence based- planning for eMTCT: Cameroon experience.

Page 0 UNITAID’s Strategic Approach to HIV Diagnostics  Washington DC 22 July, 2012 XIX International AIDS Conference Brenda Waning.

Pfizer Grassroots & Advocacy Activating Your Employees: An Rx for Success NAM Public Affairs Conference March 23, 2010.

The Hospital CAHPS Program Presented by Maureen Parrish.

GLOBAL COOPERATION FOR IP AND DEVELOPMENT Esteban Burrone Head of Policy Medicines Patent Pool.

Overview: The South African IP Policy Review 13 September 2012 MacDonald Netshitenzhe: Chief Director- Policy and Legislation.

IMPROVING ACCESS AND INNOVATION IN HIV THROUGH VOLUNTARY LICENSING: THE EXPERIENCE OF THE MEDICINES PATENT POOL ICASA – Harare, Zimbabwe Session on Innovation.

Access to medicines challenges in Europe: What is wrong and the way forward Presented by: Rohit Malpani Director of Policy & Analysis, Access Campaign.

QREDIC ® Performance assessment programme for Orange suppliers GSSC/SCS/R&VM Version: 22 nd of May 2015.

NAFTA, CAFTA and Access to Medicines and Food Security in Latin America International Aids Conference Session “Globalization and FTAs: their impact, access.

Global Access Panels Consumption 2016 Market Research Report The report focuses on global major leading industry players with information such as company.

VOLUNTARY PATENT POOLING FOR PUBLIC HEALTH A Model For Innovation And Access.

Marzena Lipman Policy Manager 5 February 2014

How Advocacy can Influence Pricing & Policy

ENSURING SECURE and RELIABLE SUPPLY and DISTRIBUTION SYSTEMS in DEVELOPING COUNTRIES, in the CONTEXT OF HIV/AIDS and PMTCT PROCUREMENT PLANNING:

Generic Competition Universities Allied for Essential Medicines

Market Research Unit 5 - slide 13.

Principles of Marketing

Moving Companies in VA Moving Companies in Washington DC.

Presentation transcript:

Washington D.C., USA, July 2012www.aids2012.org An advocacy tool: Untangling the Web of Antiretroviral Price Reductions Arax Bozadjian HIV Focused Pharmacist Access Campaign for Essential Medicines

Washington D.C., USA, July 2012www.aids2012.org Untangling the Web: 15 th edition History:  Widely varying prices between on patent and off-patent medicines  1998 Thai NGO campaign for generic fluconazole sees price drop 97% in nine months Annual publication since 2000: provides ARV pricing in response to lack of transparent and reliable information  Comprehensive pricing information provided by originator and generic manufacturers of ARVs  Source of price comparison, patent information, access issues Used as advocacy tool; quoted in publications Available online:

Washington D.C., USA, July 2012www.aids2012.org Purpose and Methodology Purpose: Help purchasers make informed decisions when purchasing ARVs for use in developing countries; used as an advocacy tool How: Details originator and generic company prices of individual ARVs; analyzes price evolution Methodology: –Questionnaire sent to companies (voluntary) –Information requested: ARV prices for developing countries; restrictions that apply to quoted prices –Generic manufacturers with at least one ARV WHO PQ are invited to participate Limitation: –No commitment from manufacturer

Washington D.C., USA, July 2012www.aids2012.org Practical use of UTW as a Tool Increased Transparency of pricing and access policies UTW provides both price and patent information Market segmentation by innovator companies Advantages of generic competition (first and second line ARVs) Historical data

Washington D.C., USA, July 2012www.aids2012.org First, Second and Third Line ARV prices at present The price of a third line regimen is 14 x more expensive than the most affordable first line regimen and over 6 x more than the most affordable second line regimen

Washington D.C., USA, July 2012www.aids2012.org First Line Regimen:TDF/3TC/EFV

Washington D.C., USA, July 2012www.aids2012.org Second Line Regimen: ATV/r

Washington D.C., USA, July 2012www.aids2012.org Third Line Regimen: Darunavir

Washington D.C., USA, July 2012www.aids2012.org Questions and/or comments? Thank You; Arax Bozadjian PharmD